Skip to main content
LXRX
NASDAQ Life Sciences

Shareholders to Vote on New Equity Plans and Charter Amendment at Annual Meeting

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
7
Price
$1.62
Mkt Cap
$682.126M
52W Low
$0.32
52W High
$1.83
Market data snapshot near publication time

summarizeSummary

Lexicon Pharmaceuticals has filed additional proxy materials outlining key proposals for its upcoming annual meeting, including new equity incentive plans and an amended certificate of incorporation.


check_boxKey Events

  • New Equity Incentive Plans Proposed

    Shareholders will vote on the 2026 Equity Incentive Plan and the 2026 Non-Employee Directors' Equity Incentive Plan, which will authorize new share issuances for compensation and could lead to future dilution.

  • Charter Amendment on Ballot

    A proposal to ratify and approve the Company's Seventh Amended and Restated Certificate of Incorporation will be presented, potentially altering corporate governance or structure.

  • Annual Meeting Scheduled

    The annual stockholder meeting is set for April 30, 2026, where these and other routine matters, including director elections and auditor ratification, will be voted upon.


auto_awesomeAnalysis

This DEFA14A provides definitive additional materials for Lexicon Pharmaceuticals' annual stockholder meeting on April 30, 2026. Key proposals include the approval of a Seventh Amended and Restated Certificate of Incorporation, which could impact corporate governance and structure, and the establishment of two new equity incentive plans for 2026. These equity plans, if approved, will authorize the issuance of new shares for employee and non-employee director compensation, leading to potential future dilution for existing shareholders. Investors should review the full proxy statement to understand the specific details and implications of these proposed changes before the vote.

At the time of this filing, LXRX was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $682.1M. The 52-week trading range was $0.32 to $1.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed LXRX - Latest Insights

LXRX
Mar 16, 2026, 4:04 PM EDT
Filing Type: DEFA14A
Importance Score:
7
LXRX
Mar 16, 2026, 4:03 PM EDT
Filing Type: DEF 14A
Importance Score:
9
LXRX
Mar 05, 2026, 4:50 PM EST
Filing Type: 10-K
Importance Score:
8
LXRX
Mar 05, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
LXRX
Mar 05, 2026, 6:59 AM EST
Source: Dow Jones Newswires
Importance Score:
7
LXRX
Feb 17, 2026, 4:12 PM EST
Filing Type: PRE 14A
Importance Score:
8
LXRX
Feb 04, 2026, 4:25 PM EST
Filing Type: 4
Importance Score:
9
LXRX
Feb 02, 2026, 9:54 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
LXRX
Feb 02, 2026, 4:49 PM EST
Filing Type: 8-K
Importance Score:
8
LXRX
Feb 02, 2026, 12:07 PM EST
Filing Type: 424B5
Importance Score:
8